Expert Opinion on Drug Delivery,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 7, 2024
Introduction
The
blood-brain
barrier
(BBB)
is
a
highly
selective
structure
that
protects
the
central
nervous
system
(CNS)
while
hindering
delivery
of
many
therapeutic
agents.
This
presents
major
challenge
in
treating
neurological
disorders,
such
as
multiple
sclerosis,
where
effective
drug
to
brain
crucial
for
improving
patient
outcomes.
Innovative
strategies
are
urgently
needed
address
this
limitation.
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(1), P. 128 - 128
Published: Jan. 17, 2025
Alzheimer's
disease
(AD)
represents
an
escalating
global
health
crisis,
constituting
the
leading
cause
of
dementia
among
elderly
and
profoundly
impairing
their
quality
life.
Current
FDA-approved
drugs,
such
as
rivastigmine,
donepezil,
galantamine,
memantine,
offer
only
modest
symptomatic
relief
are
frequently
associated
with
significant
adverse
effects.
Faced
this
challenge
in
line
advances
understanding
pathophysiology
neurodegenerative
condition,
various
innovative
therapeutic
strategies
have
been
explored.
Here,
we
review
novel
approaches
inspired
by
advanced
knowledge
underlying
pathophysiological
mechanisms
disease.
Among
alternatives,
immunotherapy
stands
out,
employing
monoclonal
antibodies
to
specifically
target
eliminate
toxic
proteins
implicated
AD.
Additionally,
use
medicinal
plants
is
examined,
synergistic
effects
components
may
confer
neuroprotective
properties.
The
modulation
gut
microbiota
also
addressed
a
peripheral
strategy
that
could
influence
neuroinflammatory
degenerative
processes
brain.
Furthermore,
potential
emerging
approaches,
microRNAs
regulate
key
cellular
nanotherapy,
which
enables
precise
drug
delivery
central
nervous
system,
analyzed.
Despite
promising
these
strategies,
incidence
continues
rise.
Therefore,
it
proposed
achieving
effective
treatment
future
require
integration
combined
maximizing
different
interventions.
Pharmaceuticals,
Journal Year:
2025,
Volume and Issue:
18(2), P. 195 - 195
Published: Jan. 31, 2025
Drugs
administered
by
means
of
extravascular
routes
drug
administration
must
be
absorbed
into
the
systemic
circulation,
which
involves
movement
molecules
across
biological
barriers
such
as
epithelial
cells
that
cover
mucosal
surfaces
or
stratum
corneum
covers
skin.
Some
drugs
exhibit
poor
permeation
membranes
may
experience
excessive
degradation
during
first-pass
metabolism,
tends
to
limit
their
bioavailability.
Various
strategies
have
been
used
improve
Absorption
enhancement
include
co-administration
chemical
enhancers,
enzymes,
and/or
efflux
transporter
inhibitors,
changes,
and
specialized
dosage
form
designs.
Models
with
physiological
relevance
are
needed
evaluate
efficacy
absorption
techniques.
in
vitro
cell
culture
models
ex
vivo
tissue
explored
quantify
effectiveness
strategies.
This
review
deliberates
on
use
for
evaluation
selected
including
nasal,
oromucosal,
pulmonary,
oral,
rectal,
transdermal
administration.
Nanoscale,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
This
review
explores
the
synergistic
potential
of
MOF-based
MNs
and
details
strategies
for
integrating
MOFs
various
guest
molecules
within
into
to
enhance
transdermal
therapeutic
applications.
